MXPA05012325A - Procedimiento para potenciar la cognicion usando zipirasidona. - Google Patents

Procedimiento para potenciar la cognicion usando zipirasidona.

Info

Publication number
MXPA05012325A
MXPA05012325A MXPA05012325A MXPA05012325A MXPA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A
Authority
MX
Mexico
Prior art keywords
mammal
formula
ziprasidone
compound
human
Prior art date
Application number
MXPA05012325A
Other languages
English (en)
Spanish (es)
Inventor
Rachel Heather Swift
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05012325A publication Critical patent/MXPA05012325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MXPA05012325A 2003-05-16 2004-05-05 Procedimiento para potenciar la cognicion usando zipirasidona. MXPA05012325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47137903P 2003-05-16 2003-05-16
PCT/IB2004/001600 WO2004100956A1 (en) 2003-05-16 2004-05-05 Method for enhancing cognition using ziprasidone

Publications (1)

Publication Number Publication Date
MXPA05012325A true MXPA05012325A (es) 2006-01-30

Family

ID=33452442

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012325A MXPA05012325A (es) 2003-05-16 2004-05-05 Procedimiento para potenciar la cognicion usando zipirasidona.

Country Status (9)

Country Link
US (2) US20050014764A1 (enExample)
EP (1) EP1626722A1 (enExample)
JP (1) JP2006528236A (enExample)
AR (1) AR044337A1 (enExample)
BR (1) BRPI0419067A (enExample)
CA (2) CA2625837A1 (enExample)
MX (1) MXPA05012325A (enExample)
TW (1) TW200507847A (enExample)
WO (1) WO2004100956A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
EP1981868A2 (en) * 2006-01-27 2008-10-22 Pfizer Products Inc. Aminophthalazine derivative compounds
JPWO2007099828A1 (ja) * 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007307638A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
CN103271906A (zh) * 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
CA2666136A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
WO2009006437A1 (en) * 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) * 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
US8293738B2 (en) 2010-05-12 2012-10-23 Abbott Laboratories Indazole inhibitors of kinase
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2016191316A1 (en) * 2015-05-22 2016-12-01 Stem Cell Theranostics, Inc. Modulation of drug-induced cardiotoxicity
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
CZ289216B6 (cs) * 1996-05-07 2001-12-12 Pfizer Inc. Trihydrát methansulfonátu 5-(2-(4-(1,2-benzizothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-onu, farmaceutická kompozice a léčivo na jeho bázi
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
WO2000059459A1 (en) * 1999-03-30 2000-10-12 Lion Corporation Hairdye composition of single preparation type containing an oxidase
EP1165083A2 (en) * 1999-04-06 2002-01-02 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
TW200507847A (en) 2005-03-01
CA2525323A1 (en) 2004-11-25
US20080269246A1 (en) 2008-10-30
AR044337A1 (es) 2005-09-07
WO2004100956A1 (en) 2004-11-25
EP1626722A1 (en) 2006-02-22
JP2006528236A (ja) 2006-12-14
CA2625837A1 (en) 2004-11-25
BRPI0419067A (pt) 2007-12-11
US20050014764A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
TW200507847A (en) Method for enhancing cognition using ziprasidone
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
MA34922B1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
DE602005004286D1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
US10493069B2 (en) Methods of treating behavioral syndromes using pipradrol
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
TW200502221A (en) Novel lactams and uses thereof
WO2001078704A3 (en) Gaba substrate and the use thereof for treating cognitive and emotional disorders
MA30592B1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
US20060199862A1 (en) Method for enhancing cognitive function
MXPA05012320A (es) Tratamientos de trastornos bipolares y sintomas asociados.
MX2007005710A (es) Sales de hidroxibenzoato de compuestos de metanicotina.
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
TW200639159A (en) Treatment of pain
WO2008018639A3 (en) Glycine transporter inhibitor
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
CA2716966A1 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
PH12022552763A1 (en) Medical use of daridorexant
TW200504036A (en) Novel lactams and uses thereof